Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression
Kyung Mi Choi, … , Joon-Yong Chung, Jun-Young Seo
Kyung Mi Choi, … , Joon-Yong Chung, Jun-Young Seo
Published October 13, 2022
Citation Information: J Clin Invest. 2022;132(24):e157302. https://doi.org/10.1172/JCI157302.
View: Text | PDF
Research Article Metabolism Oncology

The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression

  • Text
  • PDF
Abstract

Metabolic reprogramming is an important cancer hallmark. However, the mechanisms driving metabolic phenotypes of cancer cells are unclear. Here, we show that the interferon-inducible (IFN-inducible) protein viperin drove metabolic alteration in cancer cells. Viperin expression was observed in various types of cancer and was inversely correlated with the survival rates of patients with gastric, lung, breast, renal, pancreatic, or brain cancer. By generating viperin knockdown or stably expressing cancer cells, we showed that viperin, but not a mutant lacking its iron-sulfur cluster–binding motif, increased lipogenesis and glycolysis via inhibition of fatty acid β-oxidation in cancer cells. In the tumor microenvironment, deficiency of fatty acids and oxygen as well as production of IFNs upregulated viperin expression via the PI3K/AKT/mTOR/HIF-1α and JAK/STAT pathways. Moreover, viperin was primarily expressed in cancer stem-like cells (CSCs) and functioned to promote metabolic reprogramming and enhance CSC properties, thereby facilitating tumor growth in xenograft mouse models. Collectively, our data indicate that viperin-mediated metabolic alteration drives the metabolic phenotype and progression of cancer.

Authors

Kyung Mi Choi, Jeong Jin Kim, Jihye Yoo, Ku Sul Kim, Youngeun Gu, John Eom, Haengdueng Jeong, Kyungeun Kim, Ki Taek Nam, Young Soo Park, Joon-Yong Chung, Jun-Young Seo

×

Figure 1

Viperin expression in human cancer tissues and its correlation with survival of patients with cancer.

Options: View larger image (or click on image) Download as PowerPoint
Viperin expression in human cancer tissues and its correlation with surv...
(A and B) Viperin was specifically expressed in cancer tissues. (A) IHC analysis of viperin expression in human gastric (n = 114), lung (n = 165), and breast cancer (n = 78) tissues stained with a mAb against viperin (MaP.VIP). The paired adjacent noncancerous tissues were used for comparison against cancer tissues. A score of 1 was considered to represent mild expression, 2 as moderate expression, and 3 as marked expression. Scale bars: 100 μm. (B) Statistical analysis of viperin expression in cancer specimens. Pearson’s χ2 test and P values are shown for cancerous versus normal tissues. (C) Disease-specific survival of patients with gastric cancer (GC). In a subgroup (n = 51) of combined advanced-stage (pT ≥3) without lymphovascular invasion (LVI), patients with high expression of viperin had poor disease-free survival (Kaplan-Meier plot). A log-rank test (P = 0.020) was performed for patients with high and low expression of viperin. (D) Viperin expression in various cancer cell lines. Viperin protein was detected by immunoblotting using MaP.VIP. α-Tubulin was used as a loading control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts